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 College oAbstract Introduction: Sepsis is a systemic inﬂammatory response that is usually aggravated by
inappropriate immune responses, which can be inhibited by omega-3 fatty acids and antioxidants.
Objectives: To determine the efﬁcacy and safety of omega-3 fatty acid plus antioxidants in early
sepsis.
Methods: 75 patients with sepsis were divided equally into: (group A) who received high dose
omega-3 fatty acids plus ﬁxed dose antioxidants for consecutive 7 days besides conventional sepsis
treatment, (group B) who received the same treatment as group A but a lower dose of omega-3 fatty
acids and the control group who received only conventional sepsis treatment. All groups were fol-
lowed up by: Inﬂammatory markers, SOFA score monitoring, need for organ supportive measures,
length of ICU stay, 28 day mortality, ﬁnal outcome and complications.
Results: Compared to the control group, the high dose omega-3 fatty acid exhibited signiﬁcantly
lower levels of CRP, IL6 and PCT at day 7 (P= 0.047, 0.05, 0.041 respectively). Compared to the
control group, group A patients showed signiﬁcantly lesser need and shorter duration of mechanical
ventilation (P= 0.044, 0.038 respectively), signiﬁcantly reduced development of severe sepsis
indicated by mean and highest SOFA score; (P= 0.040 and 0.046 respectively), with insigniﬁcant
difference in the need for vasopressors and hemodialysis (P= 0.12, 0.6 respectively). Comparing
low dose omega-3 fatty acids plus antioxidants group to control group using same parameters,
no signiﬁcant results were found.3854729.
om (M. Hosny).
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ising effects on inﬂammatory cascade and may play a role in treatment of these patients.
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Sepsis, widely accepted as being ‘‘the systemic inﬂammatory re-
sponse syndrome that occurs after infection, is generally viewed
as a disease aggravated by the inappropriate immune response
encountered in the affected individual. Inﬂammation is part of
the normal host response to infection and injury. However,
excessive or inappropriate inﬂammation contributes to a range
of acute and chronic human diseases and is characterized by the
production of inﬂammatory cytokines, arachidonic acid-de-
rived eicosanoids (prostaglandins, thromboxanes, leukotrienes,
and other oxidized derivatives), other inﬂammatory agents (eg,
reactive oxygen species), and adhesion molecules. Thus, basic
research and clinical trials have focused on agents capable of
blocking steps within the inﬂammatory cascade [1,2].
However, despite the multitude of therapeutic approaches
evaluated, the only inﬂammation-modulating substances dem-
onstrated to date to beneﬁt patients with severe sepsis are acti-
vated protein C and low-dose hydrocortisone [3,4].
Omega-3 fatty acids are essential fatty acids, which are nec-
essary for human health but are not manufactured in the hu-
man body and we have to get them through food. They are
found in ﬁsh, such as salmon, tuna, some plants, and nut oils
[5].
Long-chain n-3 polyunsaturated fatty acids (PUFAs) de-
crease the production of inﬂammatory eicosanoids, cytokines,
and reactive oxygen species and the expression of adhesion
molecules. Thus, n-3 PUFAs are potentially potent anti-
inﬂammatory agents. As such, they may be of therapeutic
use in a variety of acute and chronic inﬂammatory settings.
Evidence of their clinical efﬁcacy is reasonably strong in some
settings (e.g., in rheumatoid arthritis) but is weak in others
(e.g., inﬂammatory bowel diseases and asthma). More, better
designed, and larger trials are required to assess the therapeutic
potential of long-chain n-3 PUFAs in inﬂammatory diseases
[6].
We aimed in our study to:
 Investigate the anti-inﬂammatory effects and safety of
short-term oral omega-3 fatty acids plus antioxidants as
an adjunctive therapy in early sepsis.
 Assess the effect of the use of omega-3 fatty acids plus anti-
oxidants on the progression of the disease to severe sepsis
and/or septic shock, and
 Evaluate the impact of this therapy on duration of ICU
stay, patient outcome and need for organ supportive
measures.
Patients and methods
We prospectively enrolled all patients with early sepsis, admit-
ted to Critical Care Department, Cairo University Hospital;
from September 2011 to July 2012. Diagnosis of sepsis wasbased on clinically suspected infection as per the treating
physician or conﬁrmed infection and 2 or more of the follow-
ing: TemperatureP 38.3or 6 36 C, Heart rate (HR) > 90/
min, Respiratory rate (RR) > 20/min or PaCO2 < 32 mmHg,
White blood cell count >12,000/mm3 or <4000/m3 or >10%
immature neutrophils. Early sepsis is deﬁned as sepsis devel-
oped within 24 h of the criteria of sepsis. An informed written
consent was given by all patients or immediate relative (ﬁrst
degree), and the study protocol was approved by the local
Review Board.
Exclusion criteria included:
(1) Age < 18 years.
(2) Signiﬁcant immunologic suppression (deﬁned as a leu-
kocyte count <5000 cells/mm3).
(3) Imminence of receiving parenteral nutrition.
(4) Presence of uncontrolled diarrhea.
(5) Recent gastrointestinal bleeding event.
(6) End stage hepatic or renal disease.
(7) Life expectancy less than 24 h.
(8) Signiﬁcant limitation of survival prognosis (deﬁned as a
life expectancy <28 days due to a chronic and/or incur-
able disease such as uncontrolled cancer or other termi-
nal disease).
(9) Pregnancy.
(10) History of allergy or intolerance to omega-3 FA
(11) Greater than 16 h after meeting inclusion criteria.
(12) Use of omega-3 in the previous weeks.
(13) Patients with severe sepsis, MOD or septic shock on
admission.
(14) APACHE II score on admission >25 (predicted mortal-
ity >80%).
Patients who met the inclusion criteria were randomized
into the study on the day of admission (if they are admitted be-
cause of sepsis) or the day they fulﬁlled the criteria of sepsis (if
they acquired sepsis during their ICU stay).
Study protocol
Studied patients were randomized into 3 groups:
High dose omega-3 plus antioxidants group (group A): these
patients received the following medications daily for 7 consec-
utive days either orally or via the nasogastric tube in addition
to the conventional treatment for sepsis:
 High doses omega-3 fatty acids (9 g in 3 divided doses) in
the form of docosahexaenoic acid and eicosapentaenoic
acid (DHA+ EPA).
 Antioxidants in the form of ascorbic acid 1000 mg/day,
Alpha-tocopherol 400 IU/12 h and selenium 100 lg/day.
Low dose omega-3 plus antioxidants group (group B): these
patients received lower doses (3 g omega-3 FA in 3 divided
Table 1 Composition of the enteral diets.
Nutrient High dose omega-3 F.A. Low dose omega-3 F.A. Control group
Protein
% of total calories 16% 16% 16%
g/day 82 82 82
Carbohydrate
% of total calories 54% 54% 54%
g/day 265 265 265
Lipid
% of total calories 30% 30% 30%
g/day 63 63 63
source 14.2% of lipid content were omega-3 FAs
85.8% other fats
4.7% of lipid content were omega-3 FAs
95.3% other fats
0% omega-3FAs
100%other fats
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tive days either orally or via the nasogastric tube) plus conven-
tional sepsis treatment.
Control group (group C): these patients received only con-
ventional sepsis treatment, which consists of treating or elimi-
nating the source of infection, timely and appropriate usage of
antimicrobial agents, hemodynamic optimization, and other
physiologic organ supportive measures.
The studied population diet was enriched with EPA, DHA,
and enhanced levels of antioxidant vitamins, although it re-
mained isocaloric and isonitrogenous to the control diet. The
full composition of the 3 groups’ diets can be found in Table 1.
Patients received enteral nutrition within 6 h of meeting the
enrollment criteria. Enteral feeding was delivered at a constant
rate to achieve a minimum of 50% basal energy expenditure
(BEE; determined using the Harris-Benedict equation) · 1.3
within the ﬁrst 24 h. If well tolerated, enteral nutrition was ad-
vanced to achieve a minimum of 75% of BEE · 1.3 within
72 h.
The omega-3 fatty acid supplementation delivered until pa-
tients were discharged or until interrupted at physician’s dis-
cretion or due to the development of any adverse event that
could be related to the omega-3 fatty acid.
All patients were followed up for a total of 28 days
(4 weeks) from study day 1 or till the day of discharge or death.
Evaluation of patients
All included patients (in all groups) were subjected to the
following:
(1) Full clinical evaluation: Including history and physical
examination with special emphasis on vital signs (BP,
HR, Temperature and RR); which were evaluated at
the day of admission and then followed daily.
(2) Laboratory investigations:(a) Routine labs: CBC (complete blood count): He-
moglobin, Hematocrit, White blood cells and pl-
atelet count. Coagulation proﬁle: PT, PC, INR
and PTT. ABGs (arterial blood gases). Liver func-
tion tests: ALT (Alanine aminotransferase), AST
(Aspartate aminotransferase), BIL (bilirubin) an-d albumin. Kidney function tests: Na, K, creati-
nine and urea. These routine labs were
withdrawn on study day 1 and subsequently there-
after every day until ICU discharge or demise or
up to a total of 28 days.
(b) Speciﬁc labs for our study: were done at day 1 then
at day 7 (after last dose of omega-3 fatty acids):
C-reactive protein (CRP), Procalcitonin (PCT),
interleukin-6 (IL-6) and lipid proﬁle: Total choles-
terol and triglycerides.(3) Microbiological studies: including pan cultures (sputum,
blood, urine or biological ﬂuid according to clinical sus-
picion) prior to antibiotic administration or after discon-
tinuation of antibiotic for 48 h.
(4) Imaging studies required to identify the source of sepsis
(e.g. chest X-ray).
(5) Clinical data: length of ICU stay, ﬁnal outcome and
need for organ supportive measures (vasopressors,
mechanical ventilation and/or hemodialysis) were
reported for all patients until ICU discharge or death
or up to a total of 28 days.
(6) Application of scoring systems: APACHE II score [7,8]
and sequential organ failure assessment (SOFA) score
[9].
Statistical analysis: Data were statistically described in
terms of mean ± standard deviation (±SD), median and
range, or frequencies (number of cases) and percentages when
appropriate. Comparison of numerical variables between the
study groups was done using Student’s t test for independent
samples when comparing 2 groups and one way analysis of
variance (ANOVA) test with posthoc 2-group comparisons
when comparing more than 2 groups. For comparing categor-
ical data, Chi square (v2) test was performed. Exact test was
used instead when the expected frequency is <5. Accuracy
was represented using the terms sensitivity, speciﬁcity, +ve
predictive value, ve predictive value, over all accuracy. P val-
ues < 0.05 were considered statistically signiﬁcant. All statisti-
cal calculations were done using computer programs SPSS
(Statistical Package for the Social Science; SPSS Inc., Chicago,
IL, USA) version 15 for Microsoft Windows.
Table 3 Comparison between group A and control as regards
the CRP, PCT and IL6 levels at day 1 and day 7.
Group A Control P-value
CRP at day1(mg/l) 55.9 ± 32.8 53.1 ± 26.6 0.64
CRP at day 7 39.3 ± 22.9 51.9 ± 14.1 0.047
PCT day1 (ng/ml) 1.36 ± 0.39 1.39 ± 0.43 0.59
PCT day 7 0.98 ± 0.72 1.46 ± 0.57 0.041
IL6 day1 136.5 ± 75 138.2 ± 80.7 0.71
IL6 day 7 89.4 ± 63 134.9 ± 95.2 0.05
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During the time period from September 2011 to July 2012, 75
patients presenting with early sepsis (chest infection in 32 pa-
tients, UTI in 8 and soft tissue infection in 35) were enrolled
in the study. Patients were randomized into 3 groups (each
consists of 25 patients):
(A) Group A (high dose omega-3 plus antioxidants group): 25
patients, 10 males and 15 females, with a mean age of
52.8 ± 18.87 presented by early sepsis from a variety
of etiologies (12 chest infection, 3 UTI and 10 soft tissue
infection).
(B) Group B (low dose omega-3 plus antioxidants group): 25
patients, 14 males and 11 females, with a mean age of
53.1 ± 12.47 presented by early sepsis from a variety
of etiologies (10 chest infection, 2 UTI and 13 soft tissue
infection).
(C) Group C (control group): 25 patients, 13 males and 12
females, with a mean age of 50.5 ± 14.77.
Baseline characteristics were comparable in groups A and
control regarding age, gender, co morbid conditions (DM,
HTN and COPD), and source of sepsis (Table 2).
The anti-inﬂammatory effect of high dose omega-3 plus
ﬁxed dose antioxidants in group A and control group was as-
sessed by serial measurements of the mean level of CRP, IL6,
and PCT at predetermined follow up days (study day 1 and 7).
At day 1 they were nearly the same in both groups (P va-
lue = 0.64, 0.54, 0.59 respectively), while at day 7; there was
a statistically signiﬁcant reduction in group A patients than
in controls as regards the mean levels of CRP (39.3 ± 22.9 ver-
sus 51.9 ± 14.1, P value = 0.047), IL6 (89.4 ± 63 versus
134.9 ± 95.2, P value = 0.05) and PCT (0.98 ± 0.72 versus
1.46 ± 0.57, P value = 0.041) (Table 3).
The mean level of TG at day 1 was nearly the same in
groups A and control [123.9 ± 39.3 for group A versus
107.8 ± 41.1 for control, P-value = 0.146] and at day 7; there
was insigniﬁcant difference between group A and control
(120.3 ± 40.3 versus 106.9 ± 41.9, P value = 0.169).
The effect of high dose omega-3 plus ﬁxed dose antioxi-
dants (group A) on clinical course was determined by the need
for organ supportive measures (vasopressors, mechanicalTable 2 Age, gender, comorbidity and source of sepsis of group A
Group A (n= 25)
Age 52.8 ± 18.87
Gender
Males 10 (40%)
Females 15 (60%)
Comorbidites
Diabetes 12 (48%)
Hypertension 13 (52%)
COPD 9 (36%)
Source of sepsis
Chest infection 12 (48%)
UTI 3 (12%)
Soft tissue infection 10 (40%)ventilation and need for acute hemodialysis). Comparing both
groups we found that group A exhibited signiﬁcantly lower
need for mechanical ventilation (P value = 0.044). However,
there were insigniﬁcant differences in the need for vasopressors
(P value = 0.123) and for acute hemodialysis (P value = 0.63)
(Fig. 1).
There was an insigniﬁcant difference between group A and
control as regards the mean length of ICU stay (11.6 ± 6.1 in
group A versus 13.9 ± 4.2 in controls, P-value = 0.124) and
the 28 day mortality (32% versus 40%, P value = 0.56). But
there was a statistically signiﬁcant reduction of the duration
of mechanical ventilation in group A patients when compared
with controls (6.7 ± 3.8 days versus 10.9 ± 6.2 days,
P-value = 0.038) (Table 4).
The severity of illness during ICU stays in both group A
and control was evaluated in each patient in the two groups
at admission (initial SOFA) and serially every day by using
sequential organ failure assessment (SOFA) score then
the mean and highest values were determined. The initial
SOFA score on admission; showed no signiﬁcant difference
(P value = 0.78). But during the hospital course there was
signiﬁcant difference between the two groups in favor of group
A, as indicated by mean SOFA score (P-value = 0.040) and
highest score (P value = 0.046) (Table 5).
There was a nonsigniﬁcant difference between group A and
control as regards the incidence of diarrhea (20% versus 16%,
P value = 0.8) or the incidence of bleeding (16% versus 12%,
P value = 0.76).
Comparing low dose omega-3 fatty acids plus antioxidants
group (group B) to control as regards the previous measure-
ments; no signiﬁcant results were found (Table 6–8).and control.
Control (n= 25) P-value
50.5 ± 14.77 0.68
13 (52%) 0.37
12 (48%) 0.42
15(60%) 0.56
12 (48%) 0.77
11 (44%) 0.46
10 (40%) 0.53
3 (12%) 1
12(48%) 0.53
0%
10%
20%
30%
40%
50%
60%
Need for V.C Need for M.V Need for H.D.
Group A
Control
Figure 1 The need for organ supportive measures in group A and control.
Table 4 Comparison between group A and control as regards the length of ICU stay, duration of mechanical ventilation and 28 day
mortality.
Group A Control P-value
Length of ICU stay (days) 11.6 ± 6.1 13.9 ± 4.2 0.124
Duration of mechanical ventilation (days) 6.7 ± 3.83 10.9 ± 6.3 0.038
28 day mortality 8 (32%) 10 (40%) 0.56
Table 6 Comparison between group B and control as regards
the CRP, PCT and IL6 levels at day 1 and day 7.
Group B Control P-value
CRP at day1 (mg/l) 52.4 ± 44 53.1 ± 26.6 0.75
CRP at day 7 47.4 ± 26 51.9 ± 14.1 0.58
PCT day1 (ng/ml) 1.37 ± 0.44 1.39 ± 0.43 0.86
PCT day 7 1.26 ± 0.91 1.46 ± 0.57 0.43
IL6 day1 136.9 ± 71.4 138.2 ± 80.7 0.81
IL6 day 7 106.8 ± 93.8 134.9 ± 95.2 0.28
Table 5 Comparison between group A and control as regards
the initial SOFA, mean SOFA, and highest SOFA scores in
both groups.
Group A Control P-value
Initial SOFA (on admission) 3.7 ± 0.96 3.6 ± 0.87 0.78
Mean SOFA (on treatment) 3.7 ± 1.2 4.9 ± 3.3 0.040
Highest SOFA (on treatment) 5.1 ± 2.8 7.5 ± 4.6 0.046
Table 8 Comparison between group B and control as regards
the initial SOFA, mean SOFA, and highest SOFA scores in
both groups.
Group B Control P-value
Initial SOFA (on admission) 3.3 ± 1.31 3.6 ± 0.87 0.51
Mean SOFA (on treatment) 4.6 ± 3.1 4.9 ± 3.3 0.77
Highest SOFA (on treatment) 6.4 ± 4.8 7.5 ± 4.6 0.59
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Currently available strategies for the management of sepsis fo-
cus on the severe forms of the disease (e.g septic shock), which
is always associated with elevated death risk [10,11]. SomeTable 7 Comparison between group B and control as regards the le
mortality.
Group
Length of ICU stay (days) 13.6 ±
Duration of mechanical ventilation (days) 8.5 ±
28 day mortality 11 (44%researchers showed that omega-3 fatty acids could reduce
inﬂammation and may help lower the risk of chronic diseases
such as heart disease, cancer, and arthritis. They are found in
ﬁsh oils and can decrease the production of inﬂammatory eico-
sanoids, reactive oxygen species and the expression of adhesion
molecules [6].
We had examined the anti-inﬂammatory effect of omega-3
fatty acids combined with antioxidants in humans as guided by
measuring serum levels of CRP, PCT and IL6 at study day 1
and day 7 which reﬂects the effect of high dose omega-3 fatty
acids combined with antioxidants on drivers of sepsis.
In the current study we found that the mean level of CRP,
IL6 and PCT at day 1 was nearly the same in both group A
and control which was elevated above the normal range, pos-
sible due to sepsis. The mean level of CRP, IL6 and PCT at
day 7 was signiﬁcantly reduced in group A compared to con-
trol (P value = 0.047, 0.05, 0.041 respectively). In concor-
dance with our study Farzaneh-Far et al. (2009) proved thatngth of ICU stay, duration of mechanical ventilation and 28 day
B Control P-value
4.1 13.9 ± 4.2 0.94
4.63 10.9 ± 6.3 0.29
) 10 (40%) 0.76
124 M. Hosny et al.among patients with stable coronary artery disease (CAD),
levels of docosahexaenoic acid (DHA) and eicosapentaenoic
acid (EPA) in erythrocyte membrane lipids were inversely
associated with CRP and IL-6. The inverse association of x-
3 fatty acids with CRP and IL-6 was not modiﬁed by multiple
variables, including statin use [12]. Also Kalogeropoulos et al.
(2010) similarly in the ATTICA study in Greece found that to-
tal plasma x-3 fatty acids were inversely associated with CRP,
IL-6, and TNF-a. [13]. Contrary to these data Tayyebi-
Khosroshahi et al. (2012) had demonstrated in a randomized
controlled trial performed on 37 patients with end-stage renal
disease undergoing dialysis, that omega-3 fatty acids supple-
mentation (3 g per day for 2 month) signiﬁcantly decreased
the serum levels of TNF-a, however the difference noted in
CRP before and after supplementation was not statistically
signiﬁcant (P > 0.05) [14].
In the current study we had examined the effect of early
high dose omega-3 plus antioxidants therapy on reducing the
degree of severe sepsis and noticed a diminished risk of devel-
opment of severe sepsis as indicated by comparing SOFA score
and clinical course during ICU stay as follows: On comparing
the initial SOFA scores between the group A and control
on admission; our data showed no signiﬁcant difference
(P value = 0.78). During the hospital course there was signif-
icant difference between both groups in favor of group A, as
indicated by mean SOFA (P-value = 0.04) and highest SOFA
(P value = 0.04). Our results are in agreement with Pontes-
Arruda et al [15] who proved that enteral nutrition with
EPA/GLA and elevated antioxidants, when used in the early
stages of sepsis in patients without any organ failure and in
need of enteral nutrition, can play a beneﬁcial role by slowing
the progression of the disease to severe sepsis and septic shock
but it was not possible to report changes of SOFA scores, as
the trial was not designed to collect daily SOFA scores [15].
Comparing group A and controls; group A exhibited signif-
icant decrease in need for mechanical ventilation (P value =
0.04); but on the other hand there was a nonsigniﬁcant
decrease in the need for vasopressors (P value = 0.12) and
acute hemodialysis (P value = 0.5).
Similar to our data, Pontes-Arruda et al [15] used enteral
nutrition with eicosapentaenoic acid (EPA), g-linolenic acid
(GLA) and antioxidants in the early treatment of sepsis in a
multicenter, prospective, randomized, double-blinded, con-
trolled study (the INTERSEPT study). Data analysis demon-
strated that patients fed the EPA/GLA diet developed less
severe sepsis and/or septic shock than patients fed the control
diet (26.3% versus 50%, respectively; P= 0.026). The patients
in the study group also had shown incidence of cardiovascular
failure (21% versus 36.2%, respectively; P= 0.038) and respi-
ratory failure (24.6% versus 39.6%, respectively; P= 0.036)
compared to the control group. The percentage of patients
fed the EPA/GLA diet requiring invasive mechanical ventila-
tion was reduced compared to controls (18.9% versus
33.9%, respectively; P= 0.394) [15].
On the other hand Rice et al (2011) in a randomized, dou-
ble-blind, placebo-controlled, multicenter trial on 272 adults
who developed acute lung injury and required mechanical ven-
tilation; found that twice-daily enteral supplementation of n-3
fatty acids, c-linolenic acid, and antioxidants did not improve
the primary end point of ventilator-free days or other clinical
outcomes in patients with acute lung injury and may be harm-
ful. Despite an 8-fold increase in plasma eicosapentaenoic acidlevels, patients receiving the n-3 supplement had fewer ventila-
tor-free days (14.0 versus 17.2; P= 0.02) and intensive care
unit-free days (14.0 versus 16.7; P= .04)). Patients in the n-3
fatty acids group also had fewer nonpulmonary organ fail-
ure–free days (12.3 versus 15.5; P= 0.02) [16].
Regarding the length of stay in the ICU, we found that
group A exhibited a non signiﬁcant reduction in the length
of ICU stay. The mean length of stay in the ICU was
11.6 ± 6.1 days for group A versus 13.9 ± 4.2 days for the
control group (P-value = 0.124).
In accordance with our results, Barbosa et al. (2010) found
that ‘‘Inclusion of ﬁsh oil in parenteral nutrition provided to
septic ICU patients increase plasma eicosapentaenoic acid,
modiﬁes inﬂammatory cytokine concentrations and improves
gas exchange. These changes are associated with a tendency to-
ward shorter length of hospital stay’’. In this study they inves-
tigated the effects of parenteral ﬁsh oil on plasma phospholipid
fatty acids, inﬂammatory mediators, and clinical outcomes on
25 patients with systemic inﬂammatory response syndrome or
sepsis, and predicted the need for parenteral nutrition. The re-
sults showed the following: Plasma interleukin (IL)-6 concen-
tration decreased signiﬁcantly more, and IL-10 signiﬁcantly
less, in the ﬁsh oil group (both P< 0.001). At day 6 the ratio
PO2/FiO2 was signiﬁcantly higher in the ﬁsh oil group
(P= 0.047) and there were fewer patients with PO2/
FiO2 < 200 and <300 in the ﬁsh oil group (P= 0.001 and
P= 0.015, respectively). However days of mechanical ventila-
tion, length of intensive care unit (ICU) stay and mortality
were not different between the two groups [17].
Lorenzo et al (2012) in randomized controlled trials com-
paring n-3 PUFA-enriched lipid emulsions with standard
non-enriched lipid emulsions in surgical and ICU patients
receiving parenteral nutrition [A total of 23 studies
(n= 1502 patients: n= 762 admitted to the ICU) were in-
cluded]; found no statistically signiﬁcant difference in mortal-
ity rate between patients receiving n-3 PUFA-enriched lipid
emulsions and those receiving standard lipid emulsions. How-
ever, n-3 PUFA-enriched emulsions are associated with a sta-
tistically and clinically signiﬁcant reduction in the infection
rate and the lengths of stay, both in the ICU and in hospital
overall [18].
In the current study we had examined the effect of early
high dose omega-3 plus antioxidants therapy on duration of
mechanical ventillation (days). The mean duration of mechan-
ical ventillation (days) was 6.7 ± 3.8 days in group A versus
10.9 ± 6.2 days in the control (P-value = 0.038); which signi-
ﬁes a statistically signiﬁcant reduction in the duration of
mechanical ventillation (days). In concordance with our results
Singer et al. (2006) performed a randomized trial on 100 arti-
ﬁcially ventilated patients admitted in ICU with ARDS or
ALI, half of them enterally received a diet enriched with eico-
sapentaenoic acid and gamma-linolenic acid. Major goals of
M.V were to reach oxygen saturation above 90%, peak airway
pressure lower than 35 cm H2O and a tidal volume of less than
7 ml/kg. The levels of PEEP and of ﬁO2 were adjusted to meet
these objectives. Compared with their baseline, the treatment
group demonstrated increases in oxygenation on days 4 and
7, which were greater than those in the control group in a sta-
tistically signiﬁcant manner. The ﬁsh oil group also did better
regarding improvement in lung compliance. There was also a
signiﬁcant difference in the length of ventilation days as com-
pared with the treatment group, but there were no signiﬁcant
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tween the two groups [19].
Regarding the complications of high dose omega-3 plus
antioxidants therapy diarrhea was more in group A (20%)
compared to the control group (16%); however this difference
was not statistically signiﬁcant (P value = 0.8). In agreement
with these data Pontes-Arruda et al. found that no statistical
difference between studied patients and control in the inci-
dence of diarrhea [16]. Opposite to that Rice et al. in their
study found that the use of the n-3 supplement resulted in more
days with diarrhea in the studied group than the control (29%
versus 21%; P= 0.001) [16].
There was a statistically nonsigniﬁcant reduction in 28 day
mortality in (group A) 32% compared to the control group
36%; however this difference was not statistically signiﬁcant
(P value = 0.26). According to Pontes-Arruda et al. no signif-
icant differences in 28-day all-cause mortality were observed
(26.2% EPA/GLA diet versus 27.6% control diet, respectively;
P= 0.72). [16] Also Rice et al. found that 60-day hospital
mortality was 26.6% in the n-3 group versus 16.3% in the con-
trol group (P= 0.05). [16].
High dose omega-3 plus antioxidants (group A) in our
study were signiﬁcantly effective in reducing the inﬂammatory
markers and improving the chest condition which was not
found when a smaller dose (group B) had been used. In accor-
dance with our results Helle et al. in their study evaluated
dose-dependent effects of parenteral supplementation of a
10% ﬁsh oil emulsion on diagnosis- and organ failure-related
outcome in a total of 661 patients receiving total parenteral
nutrition for P3 days. The primary study end point was
survival; secondary end points were length of hospital stay
and the use of antibiotics with respect to the primary
diagnosis and the extent of organ failure. The patients enrolled
in this survey were with a body mass index of 25.1 ± 4.2 and
simpliﬁed Acute Physiology Score (SAPS) II score of
32.2 ± 13.6. Length of hospital stay was 29.1 ± 18.7 days
(12.5 ± 14.8 days in the ICU). Total parenteral nutrition,
including ﬁsh oil (mean, 0.11 g/kg/day) administered for
8.7 ± 7.5 days lowered hospital mortality from 18.9% to
12.0% (p< 0.001). The ﬁsh oil dose kg/day did correlate with
beneﬁcial outcome (intensive care unit stay, hospital stay, mor-
tality). Fish oil had the most favorable effects on survival,
infection rates, and length of stay when administered in doses
between 0.1 and 0.2 g/kg/day. Lower antibiotic demand by
26% was observed when doses of 0.15–0.2 g/kg/day were used
as compared with doses of <0.05 g/kg/day. [20] Also Muraka-
mi et al. proved that among young Japanese women, the pro-
tective effect of x-3 PUFAs against HS-CRP elevation was
found only when x-3 PUFAs supplied greater than 1.1% of
dietary calories [21].
Conclusion
The use of short term high dose omega-3 fatty acids plus anti-
oxidant therapy in patients with early sepsis without associated
organ dysfunction seems to be safe and associated with prom-
ising effects on inﬂammatory cascade and may play a beneﬁ-
cial role in the treatment of these patients by contributing to
slowing the progression of sepsis-related organ dysfunction,
especially with regard to respiratory dysfunction. However, it
did not affect the 28 day mortality.Recommendations:
 We recommend using short term high dose omega-3 fatty
acids plus antioxidants therapy as an adjunctive line of
treatment in early sepsis.
 Undertake further studies with greater number of patients
to study the effect of longer-term treatment regimen on
early sepsis.
 Study the impact of omega-3 fatty acids therapy on severe
sepsis and septic shock.
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